We are live on ! Find out more
DM

Deerfield Management Portfolio holdings

AUM $8.48B
1-Year Est. Return 99.04%
This Fund
S&P 500
This Quarter Est. Return
-2.48%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$2.43B
AUM Growth
+$280M
Cap. Flow
-$9.04M
Cap. Flow %
-0.37%
Top 10 Hldgs %
37.47%
Holding
114
New
20
Increased
14
Reduced
20
Closed
12

Top Buys

Rank Stock Value
1
BPMC
Blueprint Medicines
BPMC
+$49M
2
LCI
Lannett Company, Inc.
LCI
+$46.3M
3
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$45.7M
4
ELV icon
Elevance Health
ELV
+$42.6M
5
CNC icon
Centene
CNC
+$35.6M

Top Sells

Rank Stock Value
1
DVA icon
DaVita
DVA
+$23.1M
2
PTLA
Portola Pharmaceuticals, Inc.
PTLA
+$19.2M
3
SEM
Select Medical
SEM
+$18.3M
4
TSRO
TESARO, Inc.
TSRO
+$16.4M
5
AET
Aetna Inc
AET
+$14.8M

Sector Composition

Rank Sector Weight
1 Healthcare 69.33%
2 Financials 2.39%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GBT
76
DELISTED
Global Blood Therapeutics, Inc.
GBT
$2.48M 0.1%
171,428
– –
ATXS
77
DELISTED
Astria Therapeutics
ATXS
$2.46M 0.1%
11,382
-8
-0.1% -$1.96K
KA
78
DELISTED
Kineta, Inc. Common Stock
KA
$2.28M 0.09%
1,329
– –
AGRX
79
DELISTED
Agile Therapeutics
AGRX
$2.27M 0.09%
199
+74
+59% +$1.04M
CLDX icon
80
Celldex Therapeutics
CLDX
$2.84B
$2.24M 0.09%
+42,196
New +$2.4M
OPCH icon
81
Option Care Health
OPCH
$3.4B
$2.05M 0.08%
492,807
– –
SRRA
82
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$1.74M 0.07%
29,165
-5,513
-16% -$344K
TVTY
83
DELISTED
Tivity Health, Inc. Common Stock
TVTY
$1.73M 0.07%
76,000
– –
PRTK
84
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$1.54M 0.06%
100,000
– –
NVLN
85
DELISTED
Novelion Therapeutics Inc. Common Shares
NVLN
$1.44M 0.06%
+170,454
New +$1.51M
NEOS
86
DELISTED
Neos Therapeutics, Inc
NEOS
$1.34M 0.06%
229,166
– –
OCRX
87
DELISTED
Ocera Therapeutics, Inc.
OCRX
$1.2M 0.05%
572,893
– –
MTEM
88
DELISTED
Molecular Templates, Inc.
MTEM
$971K 0.04%
13,346
– –
STRM
89
DELISTED
Streamline Health Solutions
STRM
$829K 0.03%
44,198
– –
ACUR
90
DELISTED
Acura Pharmaceuticals
ACUR
$786K 0.03%
1,025,641
– –
BMRN icon
91
BioMarin Pharmaceuticals
BMRN
$11.5B
– –
-13,800
Closed -$1.28M
DVA icon
92
DaVita
DVA
$15.2B
– –
-350,000
Closed -$23.1M
EXEL icon
93
Exelixis
EXEL
$14.1B
– –
-246,907
Closed -$3.16M
REGN icon
94
Regeneron Pharmaceuticals
REGN
$70.5B
– –
-3,300
Closed -$1.33M
SEM
95
DELISTED
Select Medical
SEM
– –
-2,514,253
Closed -$18.3M
TEVA icon
96
Teva Pharmaceuticals
TEVA
$37.4B
– –
-30,000
Closed -$1.38M
RAD
97
DELISTED
Rite Aid Corporation
RAD
– –
-13,750
Closed -$2.12M
INFI
98
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
– –
-1,935,942
Closed -$3.02M
ACOR
99
DELISTED
Acorda Therapeutics
ACOR
– –
-1,346
Closed -$3.37M
CLVS
100
DELISTED
Clovis Oncology, Inc.
CLVS
– –
-8,000
Closed -$288K
1 2 3
4
5

Similar funds

FT
Fiduciary Trust Boston, Massachusetts $8.46B AUM 21.38% 1-Year Est. Return
GRQ
Gardner Russo & Quinn Lancaster, Pennsylvania $8.5B AUM 9.79% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return
VA
Valmark Advisers Akron, Ohio $8.42B AUM 14.36% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $8.4B AUM 63.34% 1-Year Est. Return
IC
Icahn Carl Sunny Isles Beach, Florida $8.55B AUM 29.29% 1-Year Est. Return
NW
NewEdge Wealth Pittsburgh, Pennsylvania $8.39B AUM 24.47% 1-Year Est. Return
AAF
Andra AP-fonden Goteborg, Sweden $8.39B AUM 21.19% 1-Year Est. Return

Deerfield Management's Q4 2016 Portfolio in Review

As of Q4 2016, Deerfield Management held 114 positions worth $2.43B, up 13% from $2.15B the previous quarter. Its ten largest holdings account for 37% of the portfolio.

Deerfield Management's Q4 2016 filing shows 20 new, 14 increased, 20 reduced and 12 closed positions. Its largest new stake was Lannett Company, Inc.: 501,888 shares worth $44.3M. The largest sale was DaVita, an estimated $23.1M.

By sector, the portfolio is most concentrated in Healthcare at 69% of assets, down from 70% a quarter earlier, followed by Financials.

  • Deerfield Management's largest Q4 2016 buy was Lannett Company, Inc.: 501,888 shares worth $44.3M.
  • Deerfield Management added most to Blueprint Medicines in Q4 2016, an estimated $49M increase.
  • Deerfield Management's biggest Q4 2016 reduction was Portola Pharmaceuticals, Inc., cutting an estimated $19.2M.
  • Deerfield Management fully exited DaVita in Q4 2016, selling an estimated $23.1M.
  • Deerfield Management's ten largest holdings make up 37% of its $2.43B portfolio in Q4 2016.
  • Deerfield Management opened 20 new positions and closed 12 in Q4 2016.
  • Deerfield Management's portfolio value rose 13% quarter-over-quarter to $2.43B.

Based on Deerfield Management's 13F filing for Q4 2016, filed 14 Feb 2017.